Verily, an Alphabet precision health technology company, has joined forces with OneOncology, a national platform dedicated to independent oncology practices. The strategic partnership focuses on integrating Verily’s clinical trial management software, SignalPath, across practices in the OneOncology Research Network, OneR. This integration aims to enhance systems infrastructure, streamline regulatory processes, and foster collaboration with sponsors, ultimately democratizing clinical trials and promoting health equity.
Key Highlights
- Verily and OneOncology announce a strategic partnership to boost clinical trials using the SignalPath platform.
- The collaboration aims to streamline workflows for oncologists, allowing them to concentrate on patient care.
- The partnership seeks to expand research opportunities across community oncology centers, potentially increasing access to clinical trials for new cancer treatments.
Source: Business Wire
Notable Quotes
-
“Clinical trial research is core to high-quality cancer care programs. By using technology to create a platform offering from OneR, we can help enhance our partners’ clinical trial programs, which ultimately better democratizes clinical trials, and improves health equity.” – Dr. Davey Daniel, Chief Medical Officer, OneOncology
-
“Verily and OneOncology are both committed to transforming the experience for oncology practices participating in research with the latest data and technology. SignalPath delivers on that vision, easing the workflow for oncologists and their staff, so they can focus on delivering the best possible care.” – Dr. Brad Hirsch, Head of Product & Implementation at Verily and co-founder of SignalPath
SoH's Take
- The collaboration between Verily and OneOncology signifies a pivotal moment in the realm of oncology research. By integrating the SignalPath platform, the partnership aims to streamline the clinical trial process, making it more efficient and accessible. This could lead to faster discoveries and advancements in cancer care.
- The emphasis on democratizing clinical trials and promoting health equity is commendable. By leveraging technology to enhance clinical trial programs, the partnership could pave the way for more inclusive research, ensuring that a broader range of patients benefit from cutting-edge treatments.
